Idorsia Reports the Commercial Availability of Quviviq (daridorexant) in Switzerland for Chronic Insomnia Disorder
Shots:
- The company launched Quviviq, the first dual orexin receptor antagonist in Switzerland for adult patients with chronic insomnia characterized by symptoms present for 3mos. and considerable impact on daytime functioning. One 50mg tablet of Quviviq should be taken orally once every night for 30 minutes before bedtime
- The P-III program consists of two pivotal 3mos. trials published in The Lancet Neurology and a long-term extension study. The 3mos. trial results showed an improved sleep onset, sleep maintenance, and self-reported total sleep time, significant improvement from baseline over PBO in the daytime sleepiness domain of IDSIQ
- The therapy was approved in the US in Jan 2022 & was also approved in Canada in April 2023
Ref: Globenewswire | Image: Idorsia
Related News:- Idorsia’s Quviviq (daridorexant) Receives the US FDA’s Approval for the Treatment of Insomnia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
